Evidence map›Paper›PMID 42316787›Full record

ArticleProtein science : a publication of the Protein Society2026

The pivotal role of β-lactone stereochemistry in the development of SARS-CoV-2 M

Katarzyna Świderek, Vicent Moliner

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The pivotal role of β-lactone stereochemistry in the development of SARS-CoV-2 MProtein science : a publication of the Protein Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Katarzyna ŚwiderekBioComp Group, Institute of Advanced Materials, INAM, Universitat Jaume I, Castelló, Spain.ORCID 0000-0002-7528-1551
Vicent MolinerBioComp Group, Institute of Advanced Materials, INAM, Universitat Jaume I, Castelló, Spain.ORCID 0000-0002-3665-3391

Funding

Generalitat Valenciana CIPROM/2021/079Generalitat Valenciana IDIFEDER/2021/02Spanish Ministerio de Ciencia, Innovación y Universidades / Agencia Estatal de Investigación CNS2024-154238Spanish Ministerio de Ciencia, Innovación y Universidades / Agencia Estatal de Investigación PID2024-160737OB-I00
6 · The paper itself

Abstract

From the arrival of the SARS-CoV-2 coronavirus in 2019 and its associated COVID-19 pandemic, worldwide efforts have been focused on developing a drug to treat patients. The SARS-CoV-2 main protease (Mpro) is one of the main targets for drug design due to its key role in the virus replication and its distinguished ability to cleave peptides after a glutamine residue. Inspired by the knowledge of the inhibition mechanism of 20S Proteasome, this work focuses on exploring the inhibition process of SARS-CoV-2 M

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesLactonesProtease InhibitorsSARS-CoV-2Viral Nonstructural ProteinsCatalytic DomainCOVID-19HumansMolecular Dynamics SimulationStereoisomerismThermodynamicsAntiviral AgentsCoronavirus 3C ProteasesLactonesProtease InhibitorsViral Nonstructural ProteinsCOVID‐19inhibitionMDQM/MMSARS‐CoV‐2 Mproβ‐lactone

Identifiers

PMID42316787
PMCPMC13279878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.